E Stewart Geary
Chief Medical Officer, Vice President and General Manager
Eisai Co., Ltd.
Adherence to Pharmacovigilance Risk Assessment Committee guidelines
Understanding rationale, format and content for writing PSURs/PBRERs
Developing a “Benefit Maximisation Plan” toolbox for approved medicines
Reporting, evaluating and summarising safety data and signals
Incorporating communication within and across agencies to patient support programmes (PSP)
Collating patient and healthcare provider inputs from various social and digital channels
Managing variations in safety restrictions, license suspension and withdrawal
16:30 Panel Discussion: Ensuring Compliance in Patient Support Programmes (PSP): Leveraging Multi-Stakeholder Collaboration to Enhance Data Capture
• How do you realistically ensure patient adherence and prevent off-label use with the assistance of digital technologies?
• Interfacing both local and global markets research programmes to maximize data collection
• Effectively capturing all opportunities of patient interaction with pharmacists and healthcare providers to improve systematic inputs of information
• Ensuring quality standards in conduct of PSPs and Market Research Programmes (MRPs) in real-time